Author

Andreas Strasser

The University of MelbourneORCID 0000-0002-5020-4891Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:mouse· 3 Assay:flow cytometry· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Annabella ThomasiD· 2 shared Elizabeth LieschkeiD· 2 shared Gemma L. KellyiD· 2 shared Lauren Whelan· 2 shared Aisling M. RossiD· 1 shared Alexandra L. GarnhamiD· 1 shared Allan Shuai HuangiD· 1 shared Amali CoorayiD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Annabella ThomasORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pre-existing levels of pro-survival proteins and induction of BCL-XL dictate cell fate after p53 activation

Allan Shuai Huang, Elizabeth Lieschke, Pedro L. Baldoni, Annabella Thomas, Julia M. Marchingo, Lauren Whelan, Grace Khuu, Eddie La Marca, Michael J. G. Milevskiy, Aisling M. Ross, Timothy M. Johanson, Margaret A. Potts, Leonie Gibson, Vineet Vaibhav, Laura F. Dagley, , Andreas Strasser

The paper shows that pre-existing levels of pro-survival proteins and BCL-XL induction determine cell fate after p53 activation, with implications for cancer therapy.

bioRxiv · Jul 2, 2026 · PreprintCancer Biology

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugs.

Hai Vu Nguyen, Marcel Michla, Feng Yan, N. Davidson, Gemma L. Kelly, Andreas Strasser, Suzanne Cory

This study shows that losing MNT in MYC-driven lymphoma cells increases apoptosis, reduces proliferation, and makes them more sensitive to cancer drugs.

bioRxiv · May 1, 2026 · PreprintCancer Biology

Transcriptomic alterations including p53 pathway dysregulation prime DNMT3A mutant cells for transformation

Erin Lawrence, Amali Cooray, Andrew J. Kueh, Martin Pál, Lin Tai, Alexandra L. Garnham, Connie S.N. Li Wai Suen, Hannah Kate Vanyai, Quentin A. Gouil, James Lancaster, Sylvie Callegari, Lauren Whelan, Elizabeth Lieschke, Annabella Thomas, Andreas Strasser, , Marco J. Herold

This study shows DNMT3A mutations reduce DNA methylation and disrupt p53 pathway, increasing self-renewal and cancer risk in hematopoietic cells.

EMBO Reports · Apr 30, 2025Peer-reviewedCancer Biology

Early cytokine-driven adaptation of survival pathways in lymphoid cells during targeted therapies

Meng-Xiao Luo, Tania Tan, Marie Trussart, Annika Poch, Minh-Hanh Thi Nguyen, Terence Paul Speed, Damien G. Hicks, Esther Bandala‐Sanchez, Hongke Peng, Stéphane Chappaz, Charlotte A. Slade, Daniel T. Utzschneider, Rachel M. Koldej, David Ritchie, Andreas Strasser, , Daniel H.D. Gray

This study shows that CLL cells rapidly adapt to venetoclax by upregulating pro-survival proteins and cytokines, suggesting combination therapies targeting these pathways could improve treatment outcomes.

Blood · Oct 29, 2024Peer-reviewedCancer Biology